Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals for AS include easing the signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-alpha inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi / Simponi Aria, UCB’s Cimzia, and infliximab biosimilars) can reduce disease activity in AS and are very effective for patients who require more-potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). The interleukin (IL)-17 inhibitors—Novartis’s Cosentyx and Eli Lilly’s Taltz—offer an alternative mechanism of action to TNF inhibition. Pfizer’s Xeljanz and AbbVie’s Rinvoq represent the novel JAK inhibitor class—the only nonbiologic targeted therapies for AS.
Markets covered: United States
Key companies: AbbVie, Amgen, Janssen, UCB, Novartis, Eli Lilly
Key drugs: NSAIDs, Humira, Enbrel, Cimzia, Remicade, Simponi, Cosentyx, Taltz, Xeljanz, Rinvoq
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.